Clinical Trial

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-30; most recent amendment 2026-07-13.
Trial Details
NCT Number NCT07570979
Lead Sponsor Novartis Pharmaceuticals
Conditions Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment 208 participants
Start Date 2026-05-25
Primary Completion 2030-06-03 (estimated)
Study Completion 2030-06-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-14